Beta Blockers for the Treatment of Asthma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01074853|
Recruitment Status : Completed
First Posted : February 24, 2010
Last Update Posted : April 12, 2019
Current asthma medicines include inhalers. A common inhaler used in asthma is called a beta-agonist (for example salbutamol). They improve asthma symptoms by stimulating areas in the human airway resulting in widening of the human airway. Although these drugs are useful after the first dose, longterm use can cause worsening asthma symptoms.
Beta-blockers are the complete opposite type of medication. Just now they are avoided in patients with asthma as after the first dose they can cause airway narrowing and cause an asthma attack.
New research has suggested that long term use of beta-blockers can reduce airway inflammation which can improve asthma control and improve symptoms.
This research was done in asthmatic patients who didn't need inhaled steroids to control their asthma. What the investigators want to do is see if the same benefit of beta-blocker use is asthma can be seen in people who take inhaled steroids.
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Drug: propranolol Drug: placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||18 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Evaluation of Beta Blockers for the Treatment of Asthma. A Randomised Controlled Trial of Propranolol|
|Study Start Date :||May 2010|
|Actual Primary Completion Date :||March 2012|
|Actual Study Completion Date :||March 2012|
Chronic dose escalation of propranolol over period of 6 to 8 weeks.
10mg twice daily escalated to 80mg once daily
Placebo Comparator: Placebo
Matched placebo used for dose escalation period of 6 to 8 weeks
- To establish effects of chronic dosing with 'beta-blockers' on airway tone and hyperreactivity in mild asthmatics. [ Time Frame: 6 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01074853
|Asthma and Allergy Research Group, Unviersity of Dundee|
|Dundee, United Kingdom, DD1 9SY|
|Principal Investigator:||Brian J Lipworth, MD||University of Dundee|